Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 28 min read

  1. International Osteoporosis Foundation. What Is Osteoporosis? URL: www.iofbonehealth.org/what-is-osteoporosis (accessed 1 May 2019).
  2. National Institute for Health and Care Excellence. Bisphosphonates for Treating Osteoporosis. 2017. URL: www.nice.org.uk/guidance/ta464 (accessed June 2022).
  3. Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 2013;24:209–17.22832638
  4. Saito T, Sterbenz JM, Malay S, Zhong L, MacEachern MP, Chung KC. Effectiveness of antiosteoporotic drugs to prevent secondary fragility fractures: systematic review and metaanalysis. Osteoporos Int 2017;28:3289–300.28770272
  5. Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2017;12:43–9.28425085
  6. Electronic Medicines Compendium. URL: https://medicines.org.uk/emc/ (accessed 1 August 2021).
  7. Hawley S, Javaid MK, Rubin KH, Judge A, Arden NK, Vestergaard P, et al. Incidence and predictors of multiple fractures despite high adherence to oral bisphosphonates: a binational population-based Cohort study. J Bone Miner Res 2016;31:234–44.26174968
  8. Dugard MN, Jones TJ, Davie MW. Uptake of treatment for osteoporosis and compliance after bone density measurement in the community. J Epidemiol Community Health 2010;64:518–22.19679704
  9. Silverman SL, Schousboe JT, Gold DT. Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int 2011;22:21–6.20458571
  10. International Osteoporosis Foundation. The Adherence Gap: Why Osteoporosis Patients Don’t Continue with Treatment. Nyon: IOF; 2005. URL: www.iofbonehealth.org/sites/default/files/PDFs/adherence_gap_report_2005.pdf (accessed 14 May 2018).
  11. Siris ES, Gehlbach S, Adachi JD, Boonen S, Chapurlat RD, Compston JE, et al. Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int 2011;22:27–35.20358360
  12. Roh YH, Koh YD, Noh JH, Gong HS, Baek GH. Effect of health literacy on adherence to osteoporosis treatment among patients with distal radius fracture. Arch Osteoporos 2012;12:42–8.
  13. Modi A, Fan CS, Tang J, Weaver JP, Sajjan S. Association of gastrointestinal events with osteoporosis treatment initiation and treatment compliance in Germany: an observational study. Bone Rep 2016;5:208–13.28580388
  14. Raybould G, Babatunde O, Evans AL, Jordan JL, Paskins Z. Expressed information needs of patients with osteoporosis and/or fragility fractures: a systematic review. Arch Osteoporos 2018;13:14–9.29500745
  15. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44–7.18237359
  16. Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Strom O. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int 2015;26:2401–11.26282229
  17. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:1023–31.17308956
  18. Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 2013;121:1291–9.23812464
  19. Akarırmak U, Koçyiğit H, Eskiyurt N, Esmaeilzadeh S, Kuru O, Yalçinkaya EY, et al.; INSTRUCT Study Group. Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: an observational study in Turkish patients with postmenopausal osteoporosis. Acta Orthop Traumatol Turc 2016;50:415–23.27524671
  20. Kishimoto H, Maehara M. Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos 2015;10:231–9.26297076
  21. Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos 2017;12:22–9.28243883
  22. Svedbom A, Hernlund E, Ivergård M, Compston J, Cooper C, Stenmark J, et al.; EU Review Panel of IOF. The EU review panel of the IOF Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013;8:137–42.24113838
  23. Williamson S, Landeiro F, McConnell T, Fulford-Smith L, Javaid MK, Judge A, Leal J. Costs of fragility hip fractures globally: a systematic review and meta-regression analysis. Osteoporos Int 2017;28:2791–800.28748387
  24. Borgström F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 2006;17:637–50.16283064
  25. Tarride JE, Burke N, Leslie WD, Morin SN, Adachi JD, Papaioannou A, et al. Loss of health related quality of life following low-trauma fractures in the elderly. BMC Geriatr 2016;16:84–91.27093957
  26. Royal College of Physicians. National Hip Fracture Database (NHFD): Annual Report 2017. URL: www.nhfd.co.uk/files/2017ReportFiles/NHFD-AnnualReport2017.pdf (accessed 1 May 2020).
  27. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 2011;14:571–81.21669382
  28. Shalev V, Sharman Moser S, Goldshtein I, Yu J, Weil C, Ish-Shalom S, et al. Adherence With bisphosphonates and long-term risk of hip fractures: a nested case-control study using real-world data. Ann Pharmacother 2017;51:757–67.28535690
  29. Barker KL, Toye F, Minns Lowe CJ. A Qualitative Systematic Review of Patients’ Experience of Osteoporosis Using Meta-ethnography. 2016. URL: https://link.springer.com/article/10.1007/s11657-016-0286-z (accessed 1 August 2020).
  30. Raybould G, Babatunde O, Evans AL, Jordan JL, Paskins Z. Expressed Information Needs of Patients with Osteoporosis and/or Fragility Fractures: A Systematic Review. 2018. URL: https://link.springer.com/article/10.1007/s11657-018-0470-4 (accessed 1 August 2020).
  31. Hiligsmann M, Bours SPG, Boonen A. A Review of Patient Preferences for Osteoporosis Drug Treatment. 2015. URL: https://link.springer.com/content/pdf/10.1007%2Fs11926-015-0533-0.pdf (accessed 1 August 2020).
  32. Hiligsmann M, Dellaert BG, Dirksen CD, Watson V, Bours S, Goemaere S, et al. Patients’ preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. Rheumatology 2017;56:1167–76. URL: https://academic.oup.com/rheumatology/article/56/7/1167/3111548#90614539 (accessed 1 August 2020).28398547
  33. Salter C, McDaid L, Bhattacharya D, Holland R, Marshall T, Howe A. Abandoned acid? Understanding adherence to bisphosphonate medications for the prevention of osteoporosis among older women: a qualitative longitudinal study. PLOS ONE. URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0083552 (accessed 1 August 2020).
  34. Shu AD, Stedman MR, Polinski JM, Jan SA, Patel M, Truppo C, et al. Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manag Care 2009;15:417–24.19589009
  35. Nho JH, Lee YK, Ha YC, Kim CH, Suh YS, Koo KH. Can alarming improve compliance with weekly bisphosphonate in patients with osteoporosis? J Bone Metab 2016;23:51–4.27294076
  36. Seuffert P, Sagebien CA, McDonnell M, O’Hara DA. Evaluation of osteoporosis risk and initiation of a nurse practitioner intervention program in an orthopedic practice. Arch Osteoporos 2016;11:10–8.26847628
  37. Tuncel T, Hasselberg J, Peters KM. Compliance of osteoporosis patients with additional specific osteoporosis-training course. Orthopade 2017;46:256–62.27807608
  38. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014;2014:CD000011.
  39. Diez-Perez A, Naylor KE, Abrahamsen B, Agnusdei D, Brandi ML, Cooper C, et al.; Adherence Working Group of the International Osteoporosis Foundation and the European Calcified Tissue Society. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int 2017;28:767–74.28093634
  40. Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 2011;22:741–53.20589368
  41. Tremblay E, Perreault S, Dorais M. Persistence with denosumab and zoledronic acid among older women: a population-based cohort study. Arch Osteoporos 2016;11:30–8. HTA Commissioned Call 18/27.27679503
  42. Wong SM, Pacey S, Sahota O. Setting up a homecare service for zoledronic acid treatment of osteoporosis. Eur J Hosp Pharm 2016;23:364–5.31156884
  43. Marshall L, Wong SM, Sahota O. Innovative intravenous osteoporosis at home service. Age Ageing 2014;43:i10–1.
  44. www.bma.org.uk/news/2016/august/vanguards-of-an-integrated-care-revolution (accessed 1 August 2020).
  45. Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, et al. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 2016;20:1–406.
  46. Jha S, Wang Z, Laucis N, Bhattacharyya T. Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996–2012: an ecological analysis. J Bone Miner Res 2015;30:2179–87.26018247
  47. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009;15:22–33.
  48. Hiligsmann M, Bours SPG, Boonen A. A review of patient preferences for osteoporosis drug treatment. Curr Rheumatol Rep 2015;17:61–6.26286178
  49. de Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Pols HA, Koes BW, Steyerberg EW. Patients’ preferences for osteoporosis drug treatment: a discrete choice experiment. Osteoporos Int 2008;19:1029–37.18193329
  50. Alten R, Krüger K, Rellecke J, Schiffner-Rohe J, Behmer O, Schiffhorst G, Nolting HD. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence 2016;10:2217–28.27843301
  51. Feldstein AC, Schneider J, Smith DH, Vollmer WM, Rix M, Glauber H, et al. Harnessing stakeholder perspectives to improve the care of osteoporosis after a fracture. Osteoporos Int 2008;19:1527–40.18373049
  52. Bliuc D, Eisman JA, Center JR. A randomized study of two different information-based interventions on the management of osteoporosis in minimal and moderate trauma fractures. Osteoporos Int 2006;17:1309–17.16804739
  53. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res 2017;17:88–95.28126032
  54. Dejean D, Giacomini M, Simeonov D, Smith A. Finding qualitative research evidence for Health Technology Assessment. Qual Health Res 2016;26:1307–17.27117960
  55. Carroll C, Booth A, Cooper K. A worked example of ‘best fit’ framework synthesis: a systematic review of views concerning the taking of some potential chemopreventive agents. BMC Med Res Methodol 2011;11:29.21410933
  56. Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related Beliefs about Medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLOS ONE 2013;8:e80633.24312488
  57. Lewin S, Booth A, Glenton C, Munthe-Kaas H, Rashidian A, Wainwright M, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings: introduction to the series. Implement Sci 2018;13:34–29.29458394
  58. Besser SJ, Anderson JE, Weinman J. How do osteoporosis patients perceive their illness and treatment? Implications for clinical practice. Arch Osteoporos 2012;7:115–24.23225289
  59. Sale JEM, Beaton D, Sujic R, Bogoch ER. ‘If it was osteoporosis, I would have really hurt myself.’ Ambiguity about osteoporosis and osteoporosis care despite a screening programme to educate fragility fracture patients. J Eval Clin Pract 2010;16:590–6.20102434
  60. Sale JEM, Hawker G, Cameron C, Bogoch E, Jain R, Beaton D, et al. Perceived messages about bone health after a fracture are not consistent across healthcare providers. Rheumatol Int 2015;35:97–103.24962740
  61. Weston JM, Norris EV, Clark EM. The invisible disease: making sense of an osteoporosis diagnosis in older age. Qual Health Res 2011;21:1692–704.21810994
  62. Hansen CA, Abrahamsen B, Konradsen H, Pedersen BD. Women’s lived experiences of learning to live with osteoporosis: a longitudinal qualitative study. BMC Womens Health 2017;17:17–26.28279157
  63. Otmar R, Reventlow SD, Nicholson GC, Kotowicz MA, Pasco JA. General medical practitioners’ knowledge and beliefs about osteoporosis and its investigation and management. Arch Osteoporos 2012;7:107–14.23225288
  64. Jaglal SB, Carroll J, Hawker G, McIsaac WJ, Jaakkimainen L, Cadarette SM, et al. How are family physicians managing osteoporosis?: qualitative study of their experiences and educational needs. Can Fam Physician 2003;49:462–8.12729242
  65. Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. General practitioners’ insight into deprescribing for the multimorbid older individual: a qualitative study. Int J Clin Pract 2016;70:261–76.26918508
  66. Sippli K, Rieger MA, Huettig F. GPs’ and dentists’ experiences and expectations of interprofessional collaboration: findings from a qualitative study in Germany. BMC Health Serv Res 2017;17:179.28270205
  67. Merle B, Haesebaert J, Bedouet A, Barraud L, Flori M, Schott AM, Dupraz C. Osteoporosis prevention: where are the barriers to improvement in French general practitioners? A qualitative study. PLOS ONE 2019;14:e0219681.31310619
  68. Merle B, Dupraz C, Haesebaert J, Barraud L, Aussedat M, Motteau C, et al. Osteoporosis prevention: where are the barriers to improvement in a French general population? A qualitative study. Osteoporos Int 2019;30:177–85.30306220
  69. Drew S, Judge A, Cooper C, Javaid MK, Farmer A, Gooberman-Hill R. Secondary prevention of fractures after hip fracture: a qualitative study of effective service delivery. Osteoporos Int 2016;27:1719–27.26759249
  70. Alami S, Hervouet L, Poiraudeau S, Briot K, Roux C. Barriers to effective postmenopausal osteoporosis treatment: a qualitative study of patients’ and practitioners’ views. PLOS ONE 2016;11:e0158365.27355576
  71. Guzman-Clark JRS, Fang MA, Sehl ME, Traylor L, Hahn TJ. Barriers in the management of glucocorticoid-induced osteoporosis. Arthritis Care Res 2007;57:140–6.
  72. Lau E, Papaioannou A, Dolovich L, Adachi J, Sawka AM, Burns S, et al. Patients’ adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician 2008;54:394–402.18337534
  73. Salter C, McDaid L, Bhattacharya D, Holland R, Marshall T, Howe A. Abandoned acid? Understanding adherence to bisphosphonate medications for the prevention of osteoporosis among older women: a qualitative longitudinal study. PLOS ONE 2014;9:e83552. 10.1371/journal.pone.008355224392086
  74. Iversen MD, Vora RR, Servi A, Solomon DH. Factors affecting adherence to osteoporosis medications: a focus group approach examining viewpoints of patients and providers. J Geriatr Phys Ther 2011;34:72–81.21937896
  75. Mazor KM, Velten S, Andrade SE, Yood RA. Older women’s views about prescription osteoporosis medication: a cross-sectional, qualitative study. Drugs Aging 2010;27:999–1008.21087069
  76. Wozniak LA, Johnson JA, McAlister FA, Beaupre LA, Bellerose D, Rowe BH, Majumdar SR. Understanding fragility fracture patients’ decision-making process regarding bisphosphonate treatment. Osteoporos Int 2017;28:219–29.27423660
  77. Swart KMA, Van Vilsteren M, Van Hout W, Draak E, van der Zwaard BC, van der Horst HE, et al. Factors related to intentional non-initiation of bisphosphonate treatment in patients with a high fracture risk in primary care: a qualitative study. BMC Fam Pract 2018;19:141–9.30139341
  78. Scoville EA, de Leon Lovaton PP, Shah ND, Pencille LJ, Montori VM. Why do women reject bisphosphonates for osteoporosis? A videographic study. PLOS ONE 2011;6:e18468. 10.1371/journal.pone.001846821533288
  79. Sale JEM, Gignac MA, Hawker G, Frankel L, Beaton D, Bogoch E, Elliot-Gibson V. Decision to take osteoporosis medication in patients who have had a fracture and are ‘high’ risk for future fracture: a qualitative study. BMC Musculoskelet Disord 2011;12:92. 10.1186/1471-2474-12-9221554729
  80. Sturrock A, Preshaw P, Hayes C, Wilkes S. Attitudes and perceptions of GPs and community pharmacists towards their role in the prevention of bisphosphonate-related osteonecrosis of the jaw: a qualitative study in the North East of England. BMJ Open 2017;7:e016047.
  81. Sturrock A, Preshaw PM, Hayes C, Wilkes S. Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England. BMJ Open 2019;9:e024376.
  82. Nunes V, Neilson J, O’flynn N. Medicines Adherence: Involving Patients in Decisions about Prescribed Medicines and Supporting Adherence (CG76). NICE Guidance; 2009. URL: http://nice.org.uk/guidance/cg76 (accessed 25 May 2023).
  83. Horne R, Cooper V, Wileman V, Parham R, Freemantle N, Forbes A, Cooper V. Supporting adherence to medicines for long-term conditions. Eur Psychol 2019;24:82–96. 10.1027/1016-9040/a000353
  84. Driesenaar JA, De Smet PA, van Hulten R, Horne R, Zwikker H, van den Bemt B, van Dulmen S. Beliefs about inhaled corticosteroids: comparison of community pharmacists, pharmacy technicians and patients with asthma. J Asthma 2016;53:1051–8.27187172
  85. Checkland K, Harrison S, Marshall M. Is the metaphor of ‘barriers to change’ useful in understanding implementation? Evidence from general medical practice. J Heal Serv Res Policy 2007;12:95–00.
  86. Neale J. Iterative categorization (IC): a systematic technique for analysing qualitative data. Addiction 2016;111:1096–106.26806155
  87. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res 2017;17:1–13.28049468
  88. Roh YH, Noh JH, Gong HS, Baek GH. Comparative adherence to weekly oral and quarterly intravenous bisphosphonates among patients with limited heath literacy who sustained distal radius fractures. J Bone Miner Metab 2018;36:589–95.28983705
  89. Fraenkel L, Gulanski B, Wittink D. Patient treatment preferences for osteoporosis. Arthritis Care Res 2006;55:729–35.
  90. Kendler DL, Bessette L, Hill CD, Gold DT, Horne R, Varon SF, et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int 2010;21:837–46.19657689
  91. Payer J, Cierny D, Killinger Z, Sulková I, Behuliak M, Celec P. Preferences of patients with post-menopausal osteoporosis treated with bisphosphonates – the VIVA II study. J Int Med Res 2009;37:1225–9.19761708
  92. Fjose M, Eilertsen G, Kirkevold M, Grov EK. ‘Non-palliative care’ – a qualitative study of older cancer patients’ and their family members’ experiences with the health care system. BMC Health Serv Res 2018;18:745.30268149
  93. Selman LE, Bristowe K, Higginson IJ, Murtagh FEM. The views and experiences of older people with conservatively managed renal failure: a qualitative study of communication, information and decision-making. BMC Nephrol 2019;20:1–12.30606155
  94. HSJ. Daily Insight: Long-term Plan, Short-sighted Move? 2021. URL: www.hsj.co.uk/daily-insight/daily-insight-long-term-plan-short-sighted-move/7032261.article (accessed 25 May 2023).
  95. Fallowfield L, Stebbing J, Braybrooke J, Langridge C, Jenkins V. The preferences and experiences of different bisphosphonate treatments in women with breast cancer. Psycho-Oncology 2011;20:755–61.20878871
  96. Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLOS ONE 2013;8:e80633.24312488
  97. Qaseem A, Forciea MA, McLean RM, Denberg TD, Barry MJ, Cooke M, et al.; Clinical Guidelines Committee of the American College of Physicians. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 2017;166:818–39.28492856
  98. Fatoye F, Smith P, Gebrye T, Yeowell G. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 2019;9:e027049.
  99. Koller G, Goetz V, Vandermeer B, Homik J, McAlister FA, KendlerYe DC. Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int 2020;31:2093–102.32613409
  100. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012;73:691–705.22486599
  101. De Geest S, Zullig LL, Dunbar-Jacob J, Helmy R, Hughes DA, Wilson IB, Vrijens B. ESPACOMP medication adherence reporting guideline (EMERGE). Ann Intern Med 2018;169:30–5.29946690
  102. Hiligsmann M, Cornelissen D, Vrijens B, Abrahamsen B, Al- Daghri N, Biver E, et al. Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporos Int 2019;30:2155–65.31388696
  103. Chaimani A, Caldwell DM, Li T, Higgins JPT, Salanti G, Higgins JP, et al. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken: John Wiley & Sons; 2019.
  104. McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 2021;12:55–61.32336025
  105. White IR. Network meta-analysis. Stata J 2015;15:951–85.
  106. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777–84.26030634
  107. Higgins JT, Altman D, Group CSM, Group CBM. Chapter 8: Assessing risk of bias in included studies. In Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: The Cochrane Collaboration and John Wiley & Sons Ltd; 2011.
  108. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:23–9.
  109. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. (Technical Support Document in Evidence Synthesis; No. TSD2). London: National Institute for Health and Clinical Excellence; 2012.
  110. Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision making 3: heterogeneity – subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making 2013;33:618–40.23804507
  111. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163–71.20688472
  112. Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ. Chapter 4. Generalised Linear Models. Network Meta-Analysis for Decision-Making. Oxford, UK: John Wiley & Sons Ltd.; 2018.
  113. Dakin HA, Welton NJ, Ades AE, Collins S, Orme M, Kelly S. Mixed treatment comparison of repeated measurements of a continuous endpoint: an example using topical treatments for primary open-angle glaucoma and ocular hypertension. Stat Med 2011;30:2511–35.21728183
  114. Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ. Chapter 8. Meta-Regression for Relative Treatment Effects. Network Meta-Analysis for Decision-Making. Oxford, UK: John Wiley & Sons Ltd.; 2018.
  115. McKenzie JE, Brennan SE. Chapter 12: Synthesizing and presenting findings using other methods. In Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons; 2019. URL: https://training.cochrane.org/handbook/current (accessed 1 August 2020).
  116. Thomson HJ, Thomas S. The effect direction plot: visual display of non-standardised effects across multiple outcome domains. Res Synth Methods 2013;4:95–101.23795209
  117. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932–44.20213715
  118. Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ. Chapter 7. Checking for Inconsistency. Network Meta-Analysis for Decision-Making. Oxford, UK: John Wiley & Sons Ltd.; 2018.
  119. van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synth Methods 2016;7:80–93.26461181
  120. Nikolakopoulou A, Higgins JP, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, Salanti G. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLOS Med 2020;17:e1003082.32243458
  121. Papakonstantinou T, Nikolakopoulou A, Higgins JP, Egger M, Salanti G. CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell System Rev 2020;16:e1080.37131978
  122. Tan W, Sun J, Zhou L, Li Y, Wu X. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with postmenopausal osteoporosis. J Clin Pharm Ther 2016;41:519–23.27440710
  123. Hu W, Wang H, Shi X, Song Y, Zhang G, Xing S, et al. Effect of preoperative zoledronic acid administration on pain intensity after percutaneous vertebroplasty for osteoporotic vertebral compression fractures. Pain Res Manag 2020;2020:1–8.
  124. Li H, Li C, Yi X, Liu H, Wang Y. Effects of sodium alendronate on osteoporosis and apoptosisrelated factors Cyt C, Apaf-1 and caspase-9. Biomed Res 2018;29:121–9.
  125. Li Y, Zhao WB, Wang DL, He Q, Li Q, Pei FX, Liu L. Treatment of osteoporotic intertrochanteric fractures by zoledronic acid injection combined with proximal femoral nail antirotation. Chin J Traumatol 2016;19:259–63.27780504
  126. Liang BC, Shi ZY, Wang B, Wu P, Kong LC, Yao JL, et al. Intravenous zoledronic acid 5 mg on bone turnover markers and bone mineral density in East China subjects with newly diagnosed osteoporosis: a 24-month Clinical Study. Orthop Surg 2017;9:103–9.28276638
  127. Liu Z, Li CW, Mao YF, Liu K, Liang BC, Wu LG, Shi XL. Study on zoledronic acid reducing acute bone loss and fracture rates in elderly postoperative patients with intertrochanteric fractures. Orthop Surg 2019;11:380–5.31058448
  128. Shi ZY, Zhang XG, Li CW, Liu K, Liang BC, Shi XL. Effect of traditional Chinese medicine product, QiangGuYin, on bone mineral density and bone turnover in Chinese postmenopausal osteoporosis. Evid Based Complementary Altern Med 2017;2017:1–8.
  129. Zhang J, Zhang T, Xu X, Cai Q, Zhao D. Zoledronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic compression fracture in a single T12 or L1 vertebral body in postmenopausal women. Osteoporos Int 2019;30:1475–80.30976888
  130. Zhang ZL, Liao EY, Xia WB, Lin H, Cheng Q, Wang L, et al. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension. Osteoporos Int 2015;26:2719–20.26377424
  131. Zhou J, Liu B, Qin MZ, Liu JP. Fall prevention and anti-osteoporosis in osteopenia patients of 80 years of age and older: a randomized controlled study. Orthop Surg 2020;12:890–9.32495521
  132. Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. Osteoporos Int 2014;25:2729–41.25074351
  133. Eastell R, Nagase S, Ohyama M, Small M, Sawyer J, Boonen S, et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J Bone Miner Res 2011;26:1303–12.21312264
  134. Cesareo R, Di Stasio E, Vescini F, Campagna G, Cianni R, Pasqualini V, et al. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int 2015;26:1295–302.25524023
  135. Livi L, Scotti V, Desideri I, Saieva C, Cecchini S, Francolini G, et al. Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. Eur J Cancer 2019;108:100–10.30648627
  136. Popp AW, Buffat H, Cavelti A, Windolf M, Perrelet R, Senn C, Lippuner K. Cortical bone loss at the tibia in postmenopausal women with osteoporosis is associated with incident non-vertebral fractures: results of a randomized controlled ancillary study of HORIZON. Maturitas 2014;77:287–93.24485216
  137. Cosman F, Gilchrist N, McClung M, Foldes J, de Villiers T, Santora A, et al. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates. Osteoporos Int 2016;27:377–86.26556736
  138. Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med 2015;175:913–21.25867538
  139. Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen GJ, Jankowitz RC, et al. Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial. Osteoporos Int 2015;26:1857–64.25792492
  140. Grey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 2012;97:286–92.22072741
  141. Cheung AS, Hoermann R, Ghasem-Zadeh A, Tinson AJ, Ly V, Milevski SV, et al. Differing effects of zoledronic acid on bone microarchitecture and bone mineral density in men receiving androgen deprivation therapy: a randomized controlled trial. J Bone Miner Res 2020;35:1871–80.32542695
  142. Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med 2018;379:2407–16.30575489
  143. Nakamura T, Fukunaga M, Nakano T, Kishimoto H, Ito M, Hagino H, et al. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study). Osteoporos Int 2017;28:389–98.27631091
  144. Shin K, Park SH, Park W, Baek HJ, Lee YJ, Kang SW, et al. Monthly oral ibandronate reduces bone loss in Korean women with rheumatoid arthritis and osteopenia receiving long-term glucocorticoids: a 48-week double-blinded randomized placebo-controlled investigator-initiated trial. Clin Ther 2017;39:268–78.28161119
  145. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014;370:412–20.24382002
  146. Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, et al. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol 2014;15:1460–8.25456365
  147. Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2015;30:934–44.25545380
  148. Grey A, Bolland M, Mihov B, Wong S, Horne A, Gamble G, Reid IR. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial. J Bone Miner Res 2014;29:166–72.23761303
  149. Grey A, Bolland MJ, Horne A, Mihov B, Gamble G, Reid IR. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. CMAJ 2017;189:E1130–6.28893875
  150. Eastell R, Nagase S, Small M, Boonen S, Spector T, Ohyama M, et al. Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. J Bone Miner Res 2014;29:458–66.23873670
  151. Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 2020;31:1–2.
  152. Kendler DL, Marin F, Zerbini CA, Russo LA, Greenspan SL, Zikan V, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2018;391:230–40.29129436
  153. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017;377:1417–27.28892457
  154. Banefelt J, Åkesson KE, Spångeus A, Ljunggren O, Karlsson L, Ström O, et al. Risk of imminent fracture following a previous fracture in a Swedish database study. Osteoporos Int 2019;30:601–9.30680431
  155. Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle SG, Grauer A, Curtis JR. Risk of subsequent fracture after prior fracture among older women. Osteoporos Int 2019;30:79–92.30456571
  156. Noirmain C, Gil-Wey B, Pichon I, Brindel P, Haller G. Factors associated with patient willingness to participate in anaesthesia clinical trials: a vignette-based cross-sectional study. BMC Med Res Methodol 2020;20:1–0.
  157. Avis NE, Smith KW, Link CL, Hortobagyi GN, Rivera E. Factors associated with participation in breast cancer treatment clinical trials. J Clin Oncol 2006;24:1860–7.16622260
  158. Curtis JR, Yun H, Matthews R, Saag KG, Delzell E. Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res 2012;64:1054–60.
  159. Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014;348:g3318–g3318.24868083
  160. Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008;19:365–72.17938986
  161. National Osteoporosis Guideline Group. NOGG 2017: Clinical Guideline for the Prevention and Treatment of Osteoporosis; 2017. URL: https://sheffield.ac.uk/NOGG/NOGG%20Guideline%202017.pdf (accessed 10 October 2021).
  162. Morley J, Moayyeri A, Ali L, Taylor A, Feudjo-Tepie M, Hamilton L, Bayly J. Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporos Int 2020;31:533–45. 10.1007/s00198-019-05228-831758206
  163. Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012;12:9. 10.1186/1471-2288-12-922297116
  164. Spångeus A, Johansson S, Woisetschläger M. Adherence to and persistence with zoledronic acid treatment for osteoporosis – reasons for early discontinuation. Arch Osteoporos 2020;15:58. 10.1007/s11657-020-00733-432303862
  165. NHS Business Services Authority. Prescription Cost Analysis – England. March 2021. URL: www.nhsbsa.nhs.uk/prescription-data/dispensing-data/prescription-cost-analysis-pca-data (accessed 10 October 2021).
  166. Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, et al.; FLEX Research Group. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010;25:976–82.20200926
  167. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012;27:243–54.22161728
  168. Eastell R, Hannon RA, Wenderoth D, Rodriguez-Moreno J, Sawicki A. Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab 2011;96:3367–73.21865359
  169. Ravn P, Christensen JO, Baumann M, Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. Bone 1998;22:559–64.9600792
  170. Davis S, Simpson E, Hamilton J, Martyn-St James M, Rawdin A, Wong R, et al. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technol 2020;24:1–314.
  171. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654–61. 10.1136/ard.2005.04495816339289
  172. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54:1838–46.16729277
  173. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008;35:488–97.18260172
  174. Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 2010;95:4380–7.20554708
  175. van Hoek AJ, Underwood A, Jit M, Miller E, Edmunds WJ. The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. PLOS ONE 2011;6:e17030. 10.1371/journal.pone.001703021399678
  176. Curtis L, Burns A. Unit Costs of Health and Social Care 2020. Canterbury: Personal Social Services Research Unit, University of Kent; 2020. URL: www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2020/ (accessed 1 August 2020).
  177. Gutiérrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, et al. Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom. J Med Econ 2011;14:99–107.21222505
  178. Gutiérrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, et al. Clinical burden and incremental cost of fractures in postmenopausal women in the United Kingdom. Bone 2012;51:324–31.22684000
  179. Ström O, Borgström F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, et al. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 2008;79:269–80.18484255
  180. Svedbom A, Borgstöm F, Hernlund E, Ström O, Alekna V, Bianchi ML, et al. Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS. Osteoporos Int 2018;29:557–66.29230511
  181. Abimanyi-Ochom J, Watts JJ, Borgström F, Nicholson GC, Shore-Lorenti C, Stuart AL, et al. Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS). Osteoporos Int 2015;26:1781–90.25792491
  182. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013.
  183. Strong M, Oakley JE, Brennan A. Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach. Med Decis Making 2014;34:311–26.24246566
  184. Doble B, Payne R, Harshfield A, Wilson ECF. Retrospective, multicohort analysis of the Clinical Practice Research Datalink (CPRD) to determine differences in the cost of medication wastage, dispensing fees and prescriber time of issuing either short (< 60 days) or long (≥ 60 days) prescription lengths in primary care for common, chronic conditions in the UK. BMJ Open 2017;7:e019382.
  185. de Wit MP, Berlo SE, Aanerud GJ, Aletaha D, Bijlsma JW, Croucher L, et al. European league against rheumatism recommendations for the inclusion of patient representatives in scientific projects. Ann Rheum Dis 2011;70:722–6.21257615
  186. Crowe S, Fenton M, Hall M, Cowan K, Chalmers I. Patients’, clinicians’ and the research communities’ priorities for treatment research: there is an important mismatch. Res Involv Engagem 2015;1:14.29082930
  187. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 2017;8:136–45.
  188. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103:S12–9.
  189. Cochrane methods Priority Setting. Top Tips for Research Priority Setting. 2015. URL: http://methods.cochrane.org/prioritysetting/top-tips-research-priority-setting-cochrane-vienna2015-workshop (accessed 1 August 2021).
  190. Mahmood W, Jinks C, Jayakumar P, Gwilym S, Paskins Z. 115 public priority setting for research in osteoporosis. Rheumatology 2016;55:109–i110.26320140
  191. Jinks C, Carter P, Rhodes C, Taylor R, Beech R, Dziedzic K, et al. Patient and public involvement in primary care research-an example of ensuring its sustainability. Res Involv Engagem 2016;2:1.29062502
  192. Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. Lancet 2014;383:156–65.24411644
  193. Partridge N, Scadding J. The James Lind Alliance: patients and clinicians should jointly identify their priorities for clinical trials. Lancet 2014;364:1923–4.
  194. Staley K, Hanley B. Scoping Research Priority Setting (and the Presence of PPI in Priority Setting) with UK Clinical Research Organisations and Funders; 2018. James Lind Alliance Oxford.
  195. Paskins Z, Jinks C, Mahmood W, Jayakumar P, Sangan CB, Belcher J, Gwilym S. Public priorities for osteoporosis and fracture research: results from a general population survey. Arch Osteoporos 2017;12:1–8.28004295
  196. Katherine Cowan, Senior Advisor to JLA, Sandy Oliver, Professor of Public Policy at Social Science Research Unit and EPPI-Centre, Institute of Education, University of London; James Lind Alliance (JLA) Guidebook, Chapter 1. Katherine oversaw versions 1 – 5. The JLA team at the School of Healthcare Enterprise and Innovation, University of Southampton, and Katherine Cowan, with input from the JLA Advisers, have updated versions 6 onwards. URL: http://jla.nihr.ac.uk/jla-guidebook/downloads/JLA-Guidebook-Version-10-March-2021.pdf (accessed 25 May 2023).
  197. Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club 1995;123:A12–3.
  198. Katherine Cowan, Senior Advisor to JLA, Sandy Oliver, Professor of Public Policy at Social Science Research Unit and EPPI-Centre, Institute of Education, University of London; James Lind Alliance (JLA) Guidebook, Chapter 7 Report on JLA PSP online priority setting workshop – Caroline Whiting, School of Healthcare Enterprise and Innovation, University of Southampton. URL: www.jla.nihr.ac.uk/jla-guidebook/downloads/JLS-Guidebook-Version-10-2021.pdf (accessed 25 May 2023).
  199. National Institute for Health and Care Excellence (NICE). Alendronate, Etidronate, Risedronate, Raloxifene and Strontium Ranelate for the Primary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women. 2008. TAG 160. URL: https://nice.org.uk/guidance/ta160/documents/osteoporosis-secondary-prevention-including-strontium-ranelate-overview2 (accessed 1 August 2022).
  200. National Institute for Health and Care Excellence (NICE). Alendronate, Etidronate, Risedronate, Raloxifene, Strontium Ranelate and Teriparatide for the Secondary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women. 2008. TAG 161. URL: www.nice.org.uk/guidance/ta464 (accessed 1 August 2022).
  201. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010;62:1515–26.
  202. Paskins Z, Babatunde O, Sturrock A, Toh LS, Horne R, Maidment I, et al., On behalf of the Effectiveness Working Group of the Royal Osteoporosis Society Osteoporosis and Bone Research Academy. Supporting patients to get the best from their osteoporosis treatment: a rapid realist review. Osteoporos Int 2022;33:2245–57.35688897
  203. Paskins Z, Bullock L, Crawford-Manning F, Cottrell E, Fleming J, Leyland S, et al. Improving uptake of fracture prevention drug treatments: a protocol for development of a consultation intervention (iFraP-D). BMJ Open 2021;11:e048811. 10.1136/bmjopen-2021-048811
  204. Cornelissen D, Boonen A, Evers S, van den Bergh JP, Bours S, Wyers CE, et al. Improvement of osteoporosis Care Organized by Nurses: ICON study – protocol of a quasi-experimental study to assess the (cost)-effectiveness of combining a decision aid with motivational interviewing for improving medication persistence in patients with a recent fracture being treated at the fracture liaison service. BMC Musculoskelet Disord 2021;22:913. 10.1186/s12891-021-04743-234715838
  205. Sale J, Marwah A, Naeem F, Yu W, Meadows L. Evidence of patient beliefs, values, and preferences is not provided in osteoporosis clinical practice guidelines. Osteoporos Int 2019;30:1325–37. 10.1007/s00198-019-04913-y30859238
← Overall discussion and conclusionAcknowledgements →

Attribution. Opinder Sahota; Melanie Narayanasamy; Anastasios Bastounis; Zoe Paskins; Simon Bishop; Tessa Langley et al. (2024). Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study. National Institute for Health and Care Research. Copyright © 2024 Sahota et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK602864. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support